Alterity Therapeutics Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ATHE research report →
About the company
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease.
- CEO
- David A. Stamler
- IPO
- 2003
- Employees
- 10
- HQ
- Melbourne, VIC, AU
Price Chart
- Market Cap
- $48.59M
- P/E
- -9.35
- P/S
- 38.02
- P/B
- 2.51
- EV/EBITDA
- -4.81
- Div Yield
- 0.00%
- Gross Margin
- 96.82%
- Op Margin
- -525.58%
- Net Margin
- -380.65%
- ROE
- -30.19%
- ROIC
- -31.32%
- Revenue
- $5.44M · 35.32%
- Net Income
- $-12,147,828 · 36.48%
- EPS
- $-1.14 · 63.46%
- Op Income
- $-14,574,286
- FCF YoY
- 9.20%
- 52W High
- $7.00
- 52W Low
- $2.66
- 50D MA
- $4.50
- 200D MA
- $3.89
- Beta
- -0.01
- Avg Volume
- 51.15K
Get TickerSpark's AI analysis on ATHE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 15, 26 | Babarczy Julian Michael | other | 2,000,000 |
| Jun 15, 26 | Gozlan Lawrence Bernard | other | 1,000,000 |
| Apr 17, 26 | Cunningham Ann Michelle | other | 0 |
| Apr 15, 26 | Stamler David Allen | other | 0 |
| Apr 15, 26 | Stamler David Allen | other | 0 |
| Apr 15, 26 | Stamler David Allen | other | 1,515,152 |
| Apr 15, 26 | Stamler David Allen | other | 2,380,952 |
| Apr 15, 26 | Stamler David Allen | other | 40,000,200 |
| Apr 15, 26 | Stamler David Allen | other | 290,400,000 |
| Apr 10, 26 | Gozlan Lawrence Bernard | other | 0 |
Our ATHE coverage
Recent articles, reports, and earnings notes.
No research on ATHE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ATHE report →Similar companies
Peers in the same neighborhood.